Chen, S., Hellkamp, A., Becker, R., Berkowitz, S., Breithardt, G., Fox, K., … Patel, M. (2017). THROMBOLYTIC THERAPY IN ANTICOAGULATED PATIENTS: CASE SERIES FROM RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION (ROCKET AF). In Journal of the American College of Cardiology (Vol. 69, pp. 446–446). Elsevier BV. https://doi.org/10.1016/s0735-1097(17)33835-4

Chen, Sean, Anne Hellkamp, Richard Becker, Scott Berkowitz, Guenter Breithardt, Keith Fox, Werner Hacke, et al. “THROMBOLYTIC THERAPY IN ANTICOAGULATED PATIENTS: CASE SERIES FROM RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION (ROCKET AF).” In Journal of the American College of Cardiology, 69:446–446. Elsevier BV, 2017. https://doi.org/10.1016/s0735-1097(17)33835-4.

Chen S, Hellkamp A, Becker R, Berkowitz S, Breithardt G, Fox K, et al. THROMBOLYTIC THERAPY IN ANTICOAGULATED PATIENTS: CASE SERIES FROM RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION (ROCKET AF). In: Journal of the American College of Cardiology. Elsevier BV; 2017. p. 446–446.

Chen, Sean, et al. “THROMBOLYTIC THERAPY IN ANTICOAGULATED PATIENTS: CASE SERIES FROM RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION (ROCKET AF).” Journal of the American College of Cardiology, vol. 69, no. 11, Elsevier BV, 2017, pp. 446–446. Crossref, doi:10.1016/s0735-1097(17)33835-4.

Chen S, Hellkamp A, Becker R, Berkowitz S, Breithardt G, Fox K, Hacke W, Halperin J, Hankey G, Mahaffey K, Nessel C, Piccini J, Singer D, Patel M. THROMBOLYTIC THERAPY IN ANTICOAGULATED PATIENTS: CASE SERIES FROM RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION (ROCKET AF). Journal of the American College of Cardiology. Elsevier BV; 2017. p. 446–446.